Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Lingvay · SciRah

Researcher profile · Semantic Scholar

I. Lingvay

Share profile

I. Lingvay — researcher profile on SciRah

h-index: 62
Works: 264
Citations: 30K

Most-cited papers

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. Ryan, I. Lingvay, J. Deanfield, S. Kahn +16 more
2024Nature Medicine329 citations Open access
Semantic Scholar
Obesity in adults.
I. Lingvay, Ricardo V. Cohen, C. L. le Roux, P. Sumithran
2024The Lancet242 citations
Semantic Scholar
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
M. Kosiborod, J. Deanfield, R. Pratley, B. Borlaug +15 more
2024The Lancet236 citations
Semantic Scholar
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
J. Deanfield, Subodh Verma, B. Scirica, S. Kahn +16 more
2024The Lancet225 citations Open access
Semantic Scholar
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
J. Frias, Srikanth Deenadayalan, Lars Erichsen, F. Knop +5 more
2023The Lancet220 citations Open access
Semantic Scholar
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. Colhoun, I. Lingvay, Paul M. Brown, J. Deanfield +12 more
2024Nature Medicine210 citations Open access
Semantic Scholar
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
J. Deanfield, A. Lincoff, S. Kahn, S. Emerson +17 more
2025The Lancet120 citations Open access
Semantic Scholar
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Melanie J. Davies, H. Bajaj, C. Broholm, A. Eliasen +6 more
2025New England Journal of Medicine103 citations
Semantic Scholar
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Sean Wharton, I. Lingvay, Paweł Bogdański, Ruben Duque Do Vale +5 more
2025New England Journal of Medicine100 citations
Semantic Scholar
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
N. Pagidipati, A. Nelson, L. Kaltenbach, Monica Leyva +16 more
2023Journal of the American Medical Association (JAMA)93 citations Open access
Semantic Scholar
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
Sean Wharton, Paula Freitas, J. Hjelmesæth, M. Kabisch +5 more
2025The Lancet Diabetes and Endocrinology86 citations
Semantic Scholar
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
S. Kahn, J. Deanfield, O. Jeppesen, S. Emerson +15 more
2024Diabetes Care82 citations Open access
Semantic Scholar
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5)
H. Bajaj, J. Aberle, Melanie J. Davies, A. Donatsky +5 more
2023Annals of Internal Medicine77 citations
Semantic Scholar
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
I. Lingvay, J. Deanfield, S. Kahn, P. E. Weeke +13 more
2024Diabetes Care52 citations Open access
Semantic Scholar
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
I. Lingvay, O. Mosenzon, K. Brown, Xue-Wei Cui +3 more
2023Cardiovascular Diabetology52 citations Open access
Semantic Scholar
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
B. Scirica, A. Lincoff, I. Lingvay, Paweł Bogdański +15 more
2024Journal of the American College of Cardiology39 citations Open access
Semantic Scholar
Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
Arun Sanyal, Mansoor Husain, Crystel Diab, K. K. Mangla +3 more
2024American Heart Journal Plus: Cardiology Research and Practice37 citations Open access
Semantic Scholar
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
I. Lingvay, Sara J Bergenheim, John B. Buse, Paula Freitas +5 more
2025The Lancet Diabetes and Endocrinology33 citations
Semantic Scholar
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Robert F. Kushner, D. Ryan, J. Deanfield, A. Kokkinos +14 more
2025Obesity31 citations Open access
Semantic Scholar
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
I. Lingvay, M. Benamar, Liming Chen, Ariel Fu +6 more
2025Diabetologia31 citations Open access
Semantic Scholar
Type 2 diabetes mellitus.
Melanie J. Davies, Soo Lim, Tommy Slater, J. Goldney +6 more
2026Nature Reviews Disease Primers30 citations
Semantic Scholar
A revolution in obesity treatment
I. Lingvay, Shubham Agarwal
2023Nature Medicine27 citations
Semantic Scholar
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex.
Subodh Verma, H. Colhoun, Dror Dicker, G. Hovingh +8 more
2024Journal of the American College of Cardiology26 citations Open access
Semantic Scholar
Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6
Klara R. Klein, K. Clemmensen, E. Fong, Søren Olsen +2 more
2023Diabetes Care24 citations Open access
Semantic Scholar
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial
V. Aroda, Nils B. Jørgensen, Bharath Kumar, I. Lingvay +2 more
2025Diabetes Care22 citations
Semantic Scholar
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
H. Colhoun, A. Lincoff, M. Linder, S. Hardt-Lindberg +8 more
2024European Heart Journal20 citations
Semantic Scholar
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Phil McEwan, M. Bøg, Mads Faurby, V. Foos +6 more
2025Journal of Medical Economics19 citations Open access
Semantic Scholar
Obesity and its management in primary care setting
Mahmoud Ibrahim, Ebtesam M. Ba-Essa, Jessica A. Alvarez, J. Baker +29 more
2025Journal of diabetes and its complications18 citations Open access
Semantic Scholar
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity.
Subodh Verma, S. Emerson, J. Plutzky, S. Kahn +6 more
2024Journal of the American College of Cardiology17 citations Open access
Semantic Scholar
Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure.
Klara R. Klein, I. Lingvay, Katherine R. Tuttle, J. Flythe
2024Diabetes Care16 citations
Semantic Scholar
Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.
R. Bergenstal, Björg Ásbjörnsdóttir, Sara K. Watt, I. Lingvay +3 more
2024The Lancet Diabetes and Endocrinology15 citations
Semantic Scholar
Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups
I. Lingvay, J. K. Bache, Cyrus V. Desouza, M. Fragão-Marques +3 more
2025Journal of Clinical Endocrinology and Metabolism13 citations Open access
Semantic Scholar
Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease
Shu-Yao Zhang, F. Sidra, Carlos A. Alvarez, Mustafa Kinaan +2 more
2024Nature Communications13 citations Open access
Semantic Scholar
There is no magic bullet for obesity.
I. Lingvay, P. Sumithran, C. L. le Roux, R. Cohen
2023The Lancet Diabetes and Endocrinology13 citations Open access
Semantic Scholar
Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1
J. Ard, Clare J. Lee, Kimberly A. Gudzune, Brandi Addison +6 more
2025Diabetes, obesity and metabolism12 citations Open access
Semantic Scholar
Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials
V. Aroda, J. Frias, L. Ji, E. Niemoeller +7 more
2023Diabetes, obesity and metabolism12 citations Open access
Semantic Scholar
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review
J. Rosenstock, H. Bajaj, I. Lingvay, S. Heller
2024BMJ Open Diabetes Research & Care10 citations Open access
Semantic Scholar
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
Josephine L. Harrington, G. Felker, J. Januzzi, Carolyn S. P. Lam +6 more
2024Current Cardiology Reports10 citations Open access
Semantic Scholar
Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor
Marc Evans, Mansoor Husain, A. Srivastava, K. K. Mangla +2 more
2024Advances in Therapy10 citations Open access
Semantic Scholar
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial
S. Meyhöfer, B. Cariou, Cintia Cercato, H. Colhoun +19 more
2026Nature Medicine9 citations Open access
Semantic Scholar
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity.
Ricardo V. Cohen, G. Prager, C. L. le Roux, I. Lingvay +1 more
2025The Lancet Diabetes and Endocrinology7 citations
Semantic Scholar
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Adam J. Nelson, L. Kaltenbach, Darren K. McGuire, M. Levya +18 more
2024American Heart Journal7 citations
Semantic Scholar
Alterations in plasma protein N-glycosylation after caloric restriction and bariatric surgery.
T. Štambuk, D. Kifer, Valentina L. Greto, Niall J. Dempster +10 more
2024Surgery for Obesity and Related Diseases7 citations
Semantic Scholar
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial
Manasi Tannu, Lisa A. Kaltenbach, N. Pagidipati, Darren K. McGuire +21 more
2024Circulation7 citations Open access
Semantic Scholar
Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
I. Lingvay, V. Aroda, J. Honoré, A. Ersbøll +4 more
2023Journal of Diabetes7 citations Open access
Semantic Scholar
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
F. Giorgino, I. Lingvay, L. V. van Gaal, Palash Sharma +4 more
2025Diabetes Care6 citations Open access
Semantic Scholar
1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial
Sean Wharton, Paula Freitas, J. Hjelmesæth, M. Kabisch +5 more
2025Diabetes6 citations
Semantic Scholar
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease
Stephen J. Nicholls, D. Ryan, J. Deanfield, Daniel Ferreira +9 more
2025JAMA cardiology6 citations Open access
Semantic Scholar
Racial differences in quality of life in patients with heart failure treated with sodium-glucose cotransporter 2 inhibitors: A patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials
Kashvi Gupta, J. Spertus, M. Birmingham, K. Gosch +9 more
2023Circulation6 citations Open access
Semantic Scholar
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management
A. Philis-Tsimikas, J. Aberle, H. Bajaj, I. Lingvay +5 more
2025Drugs5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Lincoff×15
Invite
A. Lincoff — researcher profile on SciRah
J. Deanfield×11
Invite
J. Deanfield — researcher profile on SciRah
D. Ryan×10
Invite
D. Ryan — researcher profile on SciRah
H. Colhoun×10
Invite
H. Colhoun — researcher profile on SciRah

×8

Invite

P. E. Weeke — researcher profile on SciRah

Invite

S. Kahn — researcher profile on SciRah

Invite

J. Plutzky — researcher profile on SciRah

Invite

G. Hovingh — researcher profile on SciRah

Invite

O. Jeppesen — researcher profile on SciRah

Invite

S. Emerson — researcher profile on SciRah

Invite

V. Aroda — researcher profile on SciRah

C. L. le Roux×5

Invite

C. L. le Roux — researcher profile on SciRah